Tributary Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tributary Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,810	Closed	-$349K	–	166
2025 Q1	$349K	Hold	2,810	–	–	0.03%	143
2024 Q4	$346K	Sell	2,810 -1,230	-30%	-$145K	0.03%	148
2024 Q3	$450K	Sell	4,040 -200	-5%	-$21.9K	0.04%	141
2024 Q2	$453K	Hold	4,240	–	–	0.04%	138
2024 Q1	$511K	Sell	4,240 -250	-6%	-$30.6K	0.04%	128
2023 Q4	$552K	Sell	4,490 -100	-2%	-$12.5K	0.05%	127
2023 Q3	$594K	Sell	4,590 -100	-2%	-$13.3K	0.06%	109
2023 Q2	$581K	Buy	4,690 +1,250	+36%	+$168K	0.05%	117
2023 Q1	$503K	Buy	+3,440	New	+$509K	0.05%	128

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Tributary Capital Management's JAZZ Position: Q2 2025 in Review

Tributary Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 2,810 shares — an estimated $349K sold.

Tributary Capital Management first reported a position in JAZZ in Q1 2023 and held it in 9 quarters. The position peaked at $594K in Q3 2023. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

Tributary Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Tributary Capital Management sold 2,810 Jazz Pharmaceuticals shares in Q2 2025, an estimated $349K.
Tributary Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 9 quarters.
Tributary Capital Management's Jazz Pharmaceuticals position peaked at $594K in Q3 2023.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Tributary Capital Management's 13F filing for Q2 2025, filed 30 Jul 2025.